I agree. I have been part of a health group run by a US...

I agree.
I have been part of a health group run by a US neurosurgeon for many years, and he has always been emphasizing how inflammation is involved in pretty much all diseases.
So if ATL-1102 can be targeted to specific proteins then yes, there is a very broad area of benefit that we can attempt to assist in, to the benefit of many.

First success in the DMD trial and then it will be interesting to see where the platform can expand to.
I believe MS could be one of the first cabs off the rank, once we have ample funds. And the Tox outcome is also a potential strong trigger for MS.
It does not fit under the umbrella so much of a rare disease but considering it could have a beneficial effect, based on the 2a trials, then how could we not explore that further?
Ethically and commercially it would be appropriate.

Clarity on our future is getting much closer now, 12 months or so and we will be more informed.